Drug Profile

EVO 390

Alternative Names: EVO-390; ROR gamma t modulator - Evommune; RORγt modulator - Evommune

Latest Information Update: 23 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dermira
Developer Evommune
Class Antipsoriatics; Small molecules
Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Psoriasis

15 Sep 2021 ROR gamma t modulator - Evommune is available for licensing as of 15 Sep 2021. https://www.evommune.com/ (Evommune website, September 2021)
09 Sep 2021 Preclinical trials in Psoriasis in USA (unspecified route) before September 2021 (Evommune pipeline, September 2021)
09 Sep 2021 Evommune plans clinical trials for EVO 390 in Psoriasis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com